Viral Hepatitis
📧 Sign up to get email alerts when something new happens for Viral Hepatitis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-11-07EMA Withdrawn: Rebetol (ribavirin) — Merck Sharp and Dohme B.V
EMA withdrew Rebetol (ribavirin) from the market.
-
FDA approval · 2023-10-11FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Quinn Pharmaceuticals)
The FDA approved a supplemental application for Tenofovir disoproxil fumarate from Quinn Pharmaceuticals, granting approval of its generic p…
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016) [Phase 4]
Phase 4 study assessing safety, tolerability, and immunogenicity of the hexavalent vaccine Vaxelis in children previously vaccinated with Va…
-
FDA approval · 2023-05-05FDA Approved: LAMIVUDINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for lamivudine by Apotex Corp., enabling the generic lamivudine product to be marketed.
-
EMA withdrawal · 2022-12-15EMA Withdrawn: IntronA (interferon alfa-2b) — Merck Sharp & Dohme B.V.
The European Medicines Agency has withdrawn IntronA (interferon alfa-2b) from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-08-31FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for tenofovir disoproxil fumarate filed by Macleods Pharmaceuticals Limited under the ANDA process.
-
FDA approval · 2022-03-31FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for PROMACTA (eltrombopag olamine) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2022-03-24Clinical Trial Update: Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) [Phase 3]
A Phase 3 trial comparing different ribavirin dosages and treatment durations in combination with pegylated interferon for patients with gen…
-
EMA withdrawal · 2021-07-09EMA Withdrawn: Ribavirin Teva Pharma B.V. (ribavirin) — Teva B.V.
The EMA withdrew Ribavirin Teva Pharma B.V. (ribavirin) from the market in June 2021.
-
EMA withdrawal · 2021-07-09EMA Withdrawn: Ribavirin Teva (ribavirin) — Teva B.V.
Ribavirin Teva has been withdrawn from the European market.
-
CLINICAL_TRIALS trial_result · 2021-05-26Clinical Trial Update: Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 [Phase 1, Phase 2]
A Phase 1/Phase 2 trial investigating recovery of damaged cells to address post-COVID-19 sequelae and related conditions. Current status is …
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Efficacy of Silymarin for Acute Hepatitis [Phase 4]
Phase 4 trial update evaluating the efficacy of silymarin for acute hepatitis has completed.
-
FDA approval · 2021-03-24FDA Approved: PEGASYS — Supplemental Application (pharmaand GmbH)
FDA approved a supplemental application for Pegasys (peginterferon alfa-2a) submitted by pharmaand GmbH.
-
FDA approval · 2021-03-08FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for a generic emtricitabine and tenofovir disoproxil fumarate product from Zydus Pharmaceuticals USA…
-
FDA approval · 2021-01-26FDA Approved: LAMIVUDINE — Supplemental Application (Apotex Corp.)
FDA approves a supplemental abbreviated new drug application for Lamivudine from Apotex Corp., authorizing the continued manufacture and dis…
-
EMA withdrawal · 2020-11-23EMA Withdrawn: Ribavirin Mylan (previously Ribavirin Three Rivers) (ribavirin) — Mylan S.A.S
The EMA has withdrawn Ribavirin Mylan (ribavirin) from the market (formerly Ribavirin Three Rivers).
-
FDA approval · 2020-10-15FDA Approved: PEGASYS — Supplemental Application (pharmaand GmbH)
The FDA approved a supplemental application for PEGASYS (peginterferon alfa-2a) submitted by pharmaand GmbH.
-
CLINICAL_TRIALS trial_result · 2020-07-23Clinical Trial Update: The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of pioglitazone in patients with nonalcoholic steatohepatitis (NASH).
-
FDA approval · 2020-06-11FDA Approved: LAMIVUDINE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Lamivudine from Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2020-05-22Clinical Trial Update: Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection [Phase 4]
Phase 4 clinical trial update evaluating hepatitis B vaccination in HIV-positive individuals and those at high risk for HIV infection.
-
CLINICAL_TRIALS research · 2020-02-11Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV [Phase 2]
APhase 2 clinical trial evaluating safety, pharmacokinetics, and antiviral efficacy of SB 9200 in subjects with chronic hepatitis B.
-
FDA approval · 2020-01-23FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Camber Pharmaceuticals’ generic tenofovir disoproxil fumarate.
-
FDA approval · 2019-11-20FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Chartwell RX, LLC.)
FDA approved a supplemental application for Tenofovir disoproxil fumarate tablets from Chartwell RX, LLC. This approval authorizes the marke…
-
FDA approval · 2019-11-19FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for tenofovir disoproxil fumarate from Strides Pharma Science Limited, updating/expanding the approv…
-
FDA approval · 2019-11-19FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for tenofovir disoproxil fumarate.